Oct 27, 2026 08:00AM
Oct 27, 2026 08:00AM
Oct 13, 2026 07:01AM
Oct 13, 2026 07:01AM
Oct 13, 2026 07:00AM
Oct 13, 2026 07:00AM
Oct 8, 2026 08:00AM Entera Bio to present EB613 Phase 3 study design at ASBMR meeting
Oct 8, 2026 08:00AM
Oct 6, 2026 08:00AM
Oct 6, 2026 08:00AM
Sep 25, 2026 03:15AM
Aug 27, 2026 09:44AM
Aug 27, 2026 08:00AM
Aug 18, 2026 08:00AM Entera Bio names Riccardo Camisasca as chief medical officer
Aug 18, 2026 08:00AM
Aug 7, 2026 04:05PM
Aug 4, 2026 08:30AM
Aug 4, 2026 08:30AM
Jul 31, 2026 04:30PM
Jul 27, 2026 08:30AM
Jul 27, 2026 08:30AM Entera Bio prices $275 million private placement led by BVF Partners
Jul 27, 2026 08:30AM
Jul 27, 2026 08:30AM
Jun 24, 2026 06:46AM
Jun 22, 2026 08:30AM
Jun 22, 2026 08:30AM
Jun 16, 2026 08:33AM
Jun 16, 2026 08:33AM Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Jun 15, 2026 08:45AM
Jun 15, 2026 08:45AM
Jun 15, 2026 08:45AM
May 28, 2026 08:50AM
May 28, 2026 08:50AM
May 8, 2026 04:05PM
Apr 14, 2026 08:45AM Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Apr 2, 2026 08:46AM
Apr 2, 2026 08:45AM
Mar 27, 2026 04:05PM
Mar 4, 2026 08:30AM
Mar 4, 2026 08:30AM
Feb 11, 2026 09:03AM
Feb 11, 2026 09:00AM Entera Bio Announces Open Market Purchases of Company Stock by Board Members
Feb 9, 2026 08:50AM
Feb 9, 2026 08:50AM
Feb 4, 2026 08:02AM
Feb 4, 2026 08:00AM
Jan 21, 2026 08:31AM
Jan 21, 2026 08:30AM
Jan 21, 2026 08:30AM Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Dec 24, 2025 06:44AM

336,064 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All